Please ensure Javascript is enabled for purposes of website accessibility

Forget Sundial Growers, Canopy Growth Is a Better Marijuana Stock

By Alexander Carchidi - Feb 20, 2021 at 7:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This isn't even close to a difficult decision.

Marijuana stocks have gone wild this month. Right now, there's more than one rollercoaster ride for investors to hop on -- or to avoid if you're afraid of losing your lunch. Even rising cannabis industry stalwarts like Canopy Growth Company (CGC 4.72%) took a dive after reaching new heights. The stock is back down to $38 after spiking to a 52-week high of $56.50. But some companies are more likely to leave shareholders with a headache than others. 

In particular, the (soon to be former?) penny stock Sundial Growers (SNDL 5.41%) got lots of attention thanks to activity from Reddit traders and a subsequent pair of stock offerings worth around $174.5 million in total. Of course, most of that growth is now gone. The same can be said for Canopy, leaving investors wondering if either is worth a purchase.

Man wearing yellow, black, and white plaid button-down shirt stands in the middle of tall cannabis plants, holding one with his right hand.

Image source: Getty Images

The argument for Sundial

The investing thesis for Sundial is that it's an up-and-coming marijuana business which has the potential to grow significantly in the short-term. There are a couple of things that support this idea, namely that its adjusted gross margin is rising as its cannabis production costs fall. Furthermore, as of late December, the company is debt-free, and its general and administrative (G&A) expenses are shrinking.

Sundial is a more interesting company now than it was a year ago. After its two equity offerings earlier in February, it has over $610 million in cash. That's more than enough to fuel a transformative pivot into a new product segment, entry into a new national market like the U.S., or acquisitions of promising (and smaller) competitors. So far, Sundial has spent $22 million on an investment in the cannabis edibles manufacturer Indiva. The stake in Indiva will help to diversify its product portfolio, which is currently largely comprised of low value-added goods like dried cannabis flower. 

Why Canopy is better

As positive as its investments, fundraising, and falling costs may be, the missing ingredient for Sundial's future success is revenue growth. Net revenue from cannabis in Q3 of 2020 was only $12.9 million, which was 36% less than the previous quarter. And, over 2020, it had a 3.3% share of the Canadian cannabis market, which isn't showing any sign of increasing. In my view, both of these unfortunate facts torpedo its pitch to investors, at least for now. 

Canopy doesn't have these problems, and it's also much more established in its markets. The business holds 15.7% of the Canadian recreational cannabis market, and its share is increasing slowly over time. In the U.S., its Martha Stewart brand of cannabidiol (CBD) wellness products is outselling more than 94% of other brands, meaning that it has a commanding market share in the segment. It's also expecting more revenue from its medicinal marijuana segment in Germany, where it's the market leader.

Over the next three years, it expects its revenues to grow at a compound annual growth rate (CAGR) of at least 25% per year. In the same period, its earnings will also continue to grow, eventually becoming positive and delivering the company with free cash flows for the first time. Per its latest earnings report from earlier this week, quarterly net revenue grew by 23% year-over-year. Similarly, adjusted earnings and cash flow both improved markedly, though neither are positive yet. 

If Canopy can continue to expand while making operational improvements like it did last year, it's hard to see how its stock could severely suffer. In contrast, Sundial hasn't demonstrated that its investment pitch is valid yet, so investors should wait until it has posted a few quarters of growing revenues before considering a purchase.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$3.77 (4.72%) $0.17
Sundial Growers Inc. Stock Quote
Sundial Growers Inc.
SNDL
$0.39 (5.41%) $0.02
Indiva Limited Stock Quote
Indiva Limited
NDVA.F
$0.13 (3.61%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.